Company: REVB
Filing Date: 2025-06-04
Form Type: 8-K
Source: 0000950170-25-081604
Chunk: 1

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-06-04
Form: 8-K
Item: Item 1.01
Chunk 1
---
 to limited exceptions, offer, sell, transfer or otherwise dispose of the Company’s securities for a period of 90 days following the date of closing for the Public Offering set forth above.

On May 28, 2025, the Company also entered into a warrant agency agreement (the “ Warrant Agency Agreement”) with the Company’s transfer agent, Continental Stock Transfer & Trust Co., which acts as warrant agent for the Company, setting forth the terms and conditions of the Class H Common Stock Warrants.

As compensation in connection with the Public Offering, the Company paid the Placement Agent a cash fee of 8% of the aggregate gross proceeds raised in the Public Offering, plus reimbursement of certain expenses and legal fees.

The Common Stock, Pre-Funded Warrants and Class H Common Stock Warrants described above were offered pursuant to the Registration Statement on Form S-1 (File No. 333-287423), as amended, that was declared effective by the Securities and Exchange Commission (the “ Commission”) on May 28, 2025.

The foregoing descriptions of the Placement Agency Agreement, the Purchase Agreement, the Warrant Agency Agreement, the Pre-Funded Warrants and the Class H Common Stock Warrants do not purport to be complete and are subject to, and qualified by, the full text of such documents, copies of which are filed as Exhibits 10.1, 10.2, 4.1, 4.2 and 4.3, respectively, and incorporated by reference herein. The Placement Agency Agreement and Purchase Agreement are attached hereto as exhibits to provide interested persons with information regarding their terms, but are not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Placement Agency Agreement and Purchase Agreement were made only for purposes of such agreements as of specific dates indicated therein, were solely for the benefit of the parties thereto, and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of such agreements.

Item 3.03 Material Modification to Rights of Security Holders.